Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia
Status:
RECRUITING
Trial end date:
2027-05-20
Target enrollment:
Participant gender:
Summary
This phase II trial tests how well venetoclax works in treating patients with hairy cell leukemia that has come back after a period of improvement (relapsed). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival.
Phase:
PHASE2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Biopsy Magnetic Resonance Spectroscopy Specimen Handling Spinal Puncture venetoclax